M Cuadros1,2, V Sánchez-Martín1,2, A Herrera2,3, C Baliñas2, J Martín-Padrón1,2, L Boyero1,2, P Peinado2,3, P P Medina4,5. 1. Department of Biochemistry and Molecular Biology III and Immunology, University of Granada, Granada, Spain. 2. GENYO, Centre for Genomics and Oncological Research, Granada, Spain. 3. Department of Biochemistry and Molecular Biology I, University of Granada, Granada, Spain. 4. GENYO, Centre for Genomics and Oncological Research, Granada, Spain. pedromedina@ugr.es. 5. Department of Biochemistry and Molecular Biology I, University of Granada, Granada, Spain. pedromedina@ugr.es.
Abstract
INTRODUCTION/ PURPOSE: BRG1 is a key regulator of leukemia stem cells. Indeed, it has been observed that this type of cells is unable to divide, survive and develop new tumors when BRG1 is down-regulated. MATERIALS AND METHODS: We assessed BRG1 and miR-155 expression in 23 leukemia cell lines, and two no pathological lymphocyte samples using qPCR. MiR-155 transfection and western blot were used to analyze the relationship between miR-155 and its validated target, BRG1, by measuring protein expression levels. The effect of miR-155 on cell proliferation and prednisolone sensitivity were studied with resazurin assay. RESULTS: BRG1 expression levels could correlate negatively with miR-155 expression levels, at least in Burkitt's lymphoma and diffuse large B cell lymphoma (DLBCL) cell lines. To clarify the role of miR-155 in the regulation of BRG1 expression, we administrated miR-155 mimics in different leukemia/lymphoma cell lines. Our results suggest that miR-155 regulate negatively and significantly the BRG1 expression at least in the MOLT4 cell line. CONCLUSION: Our study revealed a previously unknown miR-155 heterogeneity that could result in differences in the treatment with miRNAs in our attempt to inhibit BRG1. However, the expression levels of BRG1 and miR-155, before prednisolone treatment were not statistically significantly associated prednisolone sensitive leukemia cells.
INTRODUCTION/ PURPOSE:BRG1 is a key regulator of leukemia stem cells. Indeed, it has been observed that this type of cells is unable to divide, survive and develop new tumors when BRG1 is down-regulated. MATERIALS AND METHODS: We assessed BRG1 and miR-155 expression in 23 leukemia cell lines, and two no pathological lymphocyte samples using qPCR. MiR-155 transfection and western blot were used to analyze the relationship between miR-155 and its validated target, BRG1, by measuring protein expression levels. The effect of miR-155 on cell proliferation and prednisolone sensitivity were studied with resazurin assay. RESULTS:BRG1 expression levels could correlate negatively with miR-155 expression levels, at least in Burkitt's lymphoma and diffuse large B cell lymphoma (DLBCL) cell lines. To clarify the role of miR-155 in the regulation of BRG1 expression, we administrated miR-155 mimics in different leukemia/lymphoma cell lines. Our results suggest that miR-155 regulate negatively and significantly the BRG1 expression at least in the MOLT4 cell line. CONCLUSION: Our study revealed a previously unknown miR-155 heterogeneity that could result in differences in the treatment with miRNAs in our attempt to inhibit BRG1. However, the expression levels of BRG1 and miR-155, before prednisolone treatment were not statistically significantly associated prednisolone sensitive leukemia cells.
Authors: Pedro P Medina; Octavio A Romero; Takashi Kohno; Luis M Montuenga; Ruben Pio; Jun Yokota; Montse Sanchez-Cespedes Journal: Hum Mutat Date: 2008-05 Impact factor: 4.878
Authors: D Gerloff; R Grundler; A A Wurm; D Bräuer-Hartmann; C Katzerke; J-U Hartmann; V Madan; C Müller-Tidow; J Duyster; D G Tenen; D Niederwieser; G Behre Journal: Leukemia Date: 2014-08-05 Impact factor: 11.528
Authors: Pedro P Medina; Julian Carretero; Mario F Fraga; Manel Esteller; David Sidransky; Montserrat Sanchez-Cespedes Journal: Genes Chromosomes Cancer Date: 2004-10 Impact factor: 5.006
Authors: Nicolas Pottier; Wenjian Yang; Mahfoud Assem; John C Panetta; Deqing Pei; Steven W Paugh; Cheng Cheng; Monique L Den Boer; Mary V Relling; Rob Pieters; William E Evans; Meyling H Cheok Journal: J Natl Cancer Inst Date: 2008-12-09 Impact factor: 13.506
Authors: Cigall Kadoch; Diana C Hargreaves; Courtney Hodges; Laura Elias; Lena Ho; Jeff Ranish; Gerald R Crabtree Journal: Nat Genet Date: 2013-05-05 Impact factor: 38.330
Authors: Marcelo L Ribeiro; Diana Reyes-Garau; Marc Armengol; Miranda Fernández-Serrano; Gaël Roué Journal: Front Genet Date: 2019-10-16 Impact factor: 4.599